If you or your patient is interested in learning more or enrolling in the Concord site of the TOMMORROW Study, please call 704-403-7658.
Carolinas HealthCare System is playing an important role in an international research study on the development and prevention of Alzheimer’s disease.
Robert Mitchell, MD, associate medical director of neurosciences for Carolinas HealthCare System and medical director of NorthEast Neurology in Concord, is serving as the primary investigator for the local site of the TOMMORROW Study. The study’s goal is to learn more about the early stages of Alzheimer’s disease in hopes of predicting and delaying its onset.
Dr. Mitchell and his team are excited to be part of an international effort to advance understanding of a condition affecting millions of people worldwide. “Through this study, we have the potential to expand our understanding of the critical early stages of the disease, and hopefully, to delay its onset,” said Dr. Mitchell.
One of the primary purposes of the TOMMORROW Study is to evaluate whether an investigational test involving two specific genes – APOE and TOMM40 – can predict a person’s risk for developing mild cognitive impairment due to Alzheimer’s disease (AD). An early phase of Alzheimer’s disease, mild cognitive impairment due to AD, is a decline in cognitive function that is significant enough to be noticed, but not severe enough to interfere with daily life or the ability to function independently.
Robert Mitchell, MD
The study also seeks to explore whether an investigational medication will delay the first symptoms of mild cognitive impairment in high-risk subjects who are cognitively normal.
The local study site, the Carolinas HealthCare System Northern Research Center located at CMC-NorthEast in Concord, is the only site for the study in the Charlotte area and one of only study two sites in the state of North Carolina. There are about 50 sites worldwide, located across North America, Europe and Australia.
Individuals who qualify for the study will be given medication and monitored regularly for five years. The study is currently enrolling cognitively normal subjects between the ages of 65 and 83 who have good physical and mental health.